Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Acta Neuropathologica

• Publication date

  2007-07-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00401-007-0261-2PMID 17653732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidoses

  2007cited by this paper
• TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation

  2007cited by this paper
• TDP-43 is deposited in the Guam parkinsonism-dementia complex brains.

  2007cited by this paper
• A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology.

  2007cited by this paper
• TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations.

  2007cited by this paper
• TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease

  2007cited by this paper
• TDP‐43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations

  2007cited by this paper
• Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43

  2007cited by this paper
• TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions.

  2007cited by this paper
• TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

  2006cited by this paper
• Frontotemporal dementia: Clinicopathological correlations

  2006cited by this paper
• Convergence of Heat Shock Protein 90 with Ubiquitin in Filamentous α-Synuclein Inclusions of α-Synucleinopathies

  2006cited by this paper
• Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies.

  2006cited by this paper
• Amyotrophic lateral sclerosis with dementia: an autopsy case showing many Bunina bodies, tau-positive neuronal and astrocytic plaque-like pathologies, and pallido-nigral degeneration

  2006cited by this paper
• Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype

  2006cited by this paper
• Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies.

  2006cited by this paper
• The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene.

  2006cited by this paper
• Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis

  2006cited by this paper
• Progressive Disruption of Cellular Protein Folding in Models of Polyglutamine Diseases

  2006cited by this paper
• Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005influential reference
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance.

  2004cited by this paper
• More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.

  2004cited by this paper
• Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

  2004cited by this paper
• Nitration of tau protein is linked to neurodegeneration in tauopathies.

  2003cited by this paper
• Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein

  2003cited by this paper
• Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases

  2002cited by this paper
• Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.

  2001cited by this paper
• Nuclear factor TDP‐43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping

  2001cited by this paper
• Diagnostic criteria for Parkinson disease.

  1999cited by this paper
• Double Immunolabeling of Neuropeptides in the Human Hypothalamus as Analyzed by Confocal Laser Scanning Fluorescence Microscopy

  1999cited by this paper
• Diagnosis and management of dementia.

  1997cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.

  1997cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

  1997cited by this paper

• Neuroimaging and Pathology Biomarkers in Parkinson’s Disease and Parkinsonism

  2026cites this paper
• ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies.

  2026cites this paper
• Inhibiting Glycogen Synthase Kinase 3 Suppresses TDP-43-Mediated Neurotoxicity in a Caspase-Dependent Manner

  2026cites this paper
• Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies—Current View

  2025influential citation
• Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies

  2025cites this paper
• The mechanisms underlying TDP-43-associated neurodegeneration in Alzheimer’s disease and related dementias

  2025cites this paper
• RNA-binding proteins in ALS and FTD: from pathogenic mechanisms to therapeutic insights

  2025cites this paper
• Zn2+ Binding Shifts the Conformational Ensemble of α‑Synuclein Monomers toward Accelerated Amyloid Formation

  2025cites this paper
• Recent Advances in Co-Condensation and Co-Aggregation of Amyloid Proteins Linked to Neurodegenerative Diseases.

  2025cites this paper
• Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration

  2025cites this paper
• Cross‐Species Transmission of SARS‐CoV‐2 From Dogs to Hamsters and Pathological Changes in the Brain

  2025cites this paper
• Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?

  2025cites this paper
• Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein

  2025cites this paper
• The levels of the long noncoding RNA MALAT1 affect cell viability and modulate TDP-43 binding to mRNA in the nucleus

  2025cites this paper
• Dementia With Lewy Bodies.

  2025cites this paper
• Assessing Co‐Localization of ITM2B With Alzheimer's Disease and Limbic‐Predominant Age‐Related TDP‐43 Encephalopathy Neuropathologic Changes

  2025cites this paper
• TDP‐43 proteinopathies and neurodegeneration: insights from Caenorhabditis elegans models

  2025cites this paper
• The Regulation of TDP-43 Structure and Phase Transitions: A Review

  2025cites this paper
• Glymphatic dysfunction in Parkinson's disease: Aging-associated impairments, imaging biomarkers, and therapeutic strategies.

  2025cites this paper
• Concomitant Pathologies and Their Impact on Parkinson Disease: A Narrative Overview of Current Evidence

  2025cites this paper
• Inhibiting glycogen synthase kinase 3 suppresses TDP-43-mediated neurotoxicity in a caspase-dependent manner

  2025cites this paper
• TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis

  2025cites this paper
• A Conserved MicroRNAs Motif Reveals TDP‐43 Pathology and MAPK Pathway Activation in Parkinson's Disease

  2025cites this paper
• Amygdalar and hippocampal volume loss in limbic-predominant age-related TDP-43 encephalopathy

  2025cites this paper
• A novel hierarchical framework elucidating regional differences in α-synuclein and tau co-pathology in military veterans with parkinsonism.

  2025cites this paper
• Distinct brain atrophy patterns in Lewy body disease: The impact and interaction of comorbid neuropathologies revealed by voxel-based morphometry

  2025cites this paper
• Detection of an Intermediate in the Unfolding Process of the N-Terminal Domain of TDP-43

  2025cites this paper
• Hydrogen–Deuterium Exchange Mass Spectrometry Reveals Mechanistic Insights into RNA Oligonucleotide-Mediated Inhibition of TDP-43 Aggregation

  2024cites this paper
• Cryptic exon inclusion is a molecular signature of LATE-NC in aging brains

  2024cites this paper
• Cytoplasmic aggregation of TDP43 and topographic correlation with tau and α-synuclein accumulation in the rTg4510 mouse model of tauopathy.

  2024cites this paper
• Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson's disease.

  2024cites this paper
• Cryo-EM structures of pathogenic fibrils and their impact on neurodegenerative disease research.

  2024cites this paper
• Novel C. elegans models of Lewy body disease reveal pathological protein interactions and widespread miRNA dysregulation

  2024cites this paper
• Amyloid-Induced Neurodegeneration: A Comprehensive Review through Aggregomics Perception of Proteins in Health and Pathology.

  2024cites this paper
• CHCHD2 P14L, found in amyotrophic lateral sclerosis, exhibits cytoplasmic mislocalization and alters Ca2+ homeostasis

  2024cites this paper
• Splicing regulation through biomolecular condensates and membraneless organelles

  2024cites this paper
• Understanding age-related pathologic changes in TDP-43 functions and their consequence on RNA splicing and signalling in health and disease.

  2024cites this paper
• Protein-protein interactions regulating α-synuclein pathology.

  2024cites this paper
• Biophysical characterization of the phase separation of TDP-43 devoid of the C-terminal domain

  2024cites this paper
• Role of Amyloidogenic and Non‐Amyloidogenic Protein Spaces in Neurodegenerative Diseases and their Mitigation Using Theranostic Agents

  2024cites this paper
• Co-Aggregation of TDP-43 with Other Pathogenic Proteins and Their Co-Pathologies in Neurodegenerative Diseases

  2024cites this paper
• RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy

  2023cites this paper
• Prevalence of Concomitant Pathologies in Parkinson’s Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms

  2023cites this paper
• Secondary Protein Aggregates in Neurodegenerative Diseases: Almost the Rule Rather than the Exception.

  2023cites this paper
• Protective Effect of Glucocorticoids against Symptomatic Disease in CSF1R Variant Carriers

  2023cites this paper
• Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers

  2023cites this paper
• Moderate intrinsic phenotypic alterations in C9orf72 ALS/FTD iPSC-microglia despite the presence of C9orf72 pathological features

  2023influential citation
• Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases

  2023cites this paper
• Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage

  2023cites this paper
• Concomitant protein pathogenesis in Parkinson’s disease and perspective mechanisms

  2023cites this paper
• Comparison of Clinical, Genetic, and Pathologic Features of Limbic and Diffuse Transactive Response DNA-Binding Protein 43 Pathology in Alzheimer’s Disease Neuropathologic Spectrum

  2023cites this paper
• Pathophysiology and Neuroimmune Interactions Underlying Parkinson’s Disease and Traumatic Brain Injury

  2023cites this paper
• RNA Binding Proteins in Senescence: A Potential Common Linker for Age-related Diseases?

  2023cites this paper
• Mixed pathology as a rule, not exception: Time to reconsider disease nosology.

  2023cites this paper
• Structural polymorphism of the low-complexity C-terminal domain of TDP-43 amyloid aggregates revealed by solid-state NMR

  2023cites this paper
• Identification and functional characterization of a bipartite nuclear localization signal in ANKRD11.

  2023cites this paper
• Patterns of TDP‐43 Deposition in Brains with LRRK2 G2019S Mutations

  2023cites this paper
• Comprehensive mapping of mutations in TDP-43 and α-Synuclein that affect stability and binding

  2023influential citation
• Towards Understanding Neurodegenerative Diseases: Insights from Caenorhabditis elegans

  2023cites this paper
• Neuronal loss of the nucleus basalis of Meynert in primary progressive aphasia is associated with Alzheimer's disease neuropathological changes

  2022cites this paper
• Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease

  2022cites this paper
• Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers

  2022cites this paper
• Transcriptional targets of amyotrophic lateral sclerosis/frontotemporal dementia protein TDP-43 – meta-analysis and interactive graphical database

  2022cites this paper
• Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s Patients

  2022cites this paper
• Similar neuronal imprint and no cross-seeded fibrils in α-synuclein aggregates from MSA and Parkinson’s disease

  2022cites this paper
• Neuropathology and neuroanatomy of TDP-43 amyotrophic lateral sclerosis

  2022cites this paper
• Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?

  2022cites this paper
• Liquid-liquid phase separation of α-Synuclein: A new mechanistic insight for α-Synuclein aggregation associated with Parkinson's disease pathogenesis.

  2022cites this paper
• Genetics and Pathogenesis of Parkinson’s Syndrome

  2022cites this paper
• A systems biology approach to understand the role of TDP-43 in amyotrophic lateral sclerosis

  2022cites this paper
• Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design

  2022cites this paper
• Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies

  2022cites this paper
• A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43

  2022cites this paper
• Prionoids in amyotrophic lateral sclerosis

  2022cites this paper
• The Role of TDP-43 in Neurodegenerative Disease

  2022cites this paper
• Parallel Appearance of Polyglutamine and Transactivation-Responsive DNA-Binding Protein 43 and Their Complementary Subcellular Localization in Brains of Patients With Spinocerebellar Ataxia Type 2.

  2022cites this paper
• Distinct neurotoxic TDP-43 fibril polymorphs are generated by heterotypic interactions with α-Synuclein

  2022cites this paper
• Neuropathological changes in advanced Parkinson’s disease

  2022cites this paper
• Brain pathological changes from population-based studies

  2022cites this paper
• Microglia phenotypes are associated with subregional patterns of concomitant tau, amyloid-β and α-synuclein pathologies in the hippocampus of patients with Alzheimer’s disease and dementia with Lewy bodies

  2022cites this paper
• Morphological basis of Parkinson disease-associated cognitive impairment: an update

  2022cites this paper
• TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links?

  2022cites this paper
• TDP-43 and neurodegenerative diseases

  2022cites this paper
• The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson’s disease

  2022cites this paper
• Role of Triggers on the Structural and Functional Facets of TDP-43.

  2022cites this paper
• Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.

  2022cites this paper
• Biophysical characterization of full‐length TAR DNA‐binding protein (TDP‐43) phase separation

  2022cites this paper
• In Vitro Interaction of a C-Terminal Fragment of TDP-43 Protein with Human Serum Albumin Modulates Its Aggregation.

  2022cites this paper
• Neocortical Lewy Body Pathology Parallels Parkinson's Dementia, but Not Always

  2022cites this paper
• Incidence and morphology of secondary TDP-43 proteinopathies: Part 1.

  2022cites this paper
• Mechanism underlying a risk gene in neurodegeneration

  2022cites this paper
• Huntingtin and Other Neurodegeneration-Associated Proteins in the Development of Intracellular Pathologies: Potential Target Search for Therapeutic Intervention

  2022cites this paper
• Neuropathological substrates of cognition in Parkinson's disease.

  2022cites this paper
• TAR DNA‐binding protein 43 oligomers in physiology and pathology

  2022cites this paper
• A C-Terminally Truncated TDP-43 Splice Isoform Exhibits Neuronal Specific Cytoplasmic Aggregation and Contributes to TDP-43 Pathology in ALS

  2022cites this paper
• Severe cerebrovascular pathology of the first supercentenarian to be autopsied in the world

  2022cites this paper
• Structural dissection of TDP-43

  2022cites this paper
• An in situ and in vitro investigation of cytoplasmic TDP-43 inclusions reveals the absence of a clear amyloid signature

  2022cites this paper
• A Microplate-Based Approach to Map Interactions between TDP-43 and α-Synuclein

  2022cites this paper
• Novel and known transcriptional targets of ALS/FTD protein TDP-43: Meta-analysis and interactive graphical databases

  2021cites this paper